Literature DB >> 18176911

Effects of normalization of plasma testosterone levels in hypogonadal men on plasma levels and urinary excretion of asymmetric dimethylarginine (ADMA).

E Leifke1, M Kinzel, D Tsikas, L Gooren, J C Frölich, G Brabant.   

Abstract

Elevated plasma levels of asymmetric dimethylarginine (ADMA) inhibit nitric oxide formation and exert a proatherogenic action. Low testosterone (T) levels are associated with increased cardiovascular risks. This study analyzed the effects of normalization of plasma T levels on plasma levels and urinary excretion of ADMA in hypgonadal men (n=10) receiving transdermal T administration. Plasma T levels, starting from clearly hypogonadal T plasma concentrations with a mean level of 4.0+/-2.72 nmol/l at baseline, rose to >10 nmol/l after 2 weeks, with plasma T levels within the normal range of men (mean level of 22.5+/-11.3 nmol/l) over the last 16 weeks of the 24 weeks of T administration. Normalization of plasma T led to a small but significant fall of plasma ADMA (519+/-55 vs. 472+/-59 nmol/l, p=0.031). The outcome of this study may be viewed as a favorable effect of normalization of plasma testosterone on plasma ADMA since even small elevations of plasma ADMA significantly increase cardiovascular risk. While this effect of normalization of plasma T may impress as favorable, most available studies on effects of T administration to hypogonadal men have not shown beneficial effects on functions of the vascular wall.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18176911     DOI: 10.1055/s-2007-1004529

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  3 in total

Review 1.  Onset of effects of testosterone treatment and time span until maximum effects are achieved.

Authors:  Farid Saad; Antonio Aversa; Andrea M Isidori; Livia Zafalon; Michael Zitzmann; Louis Gooren
Journal:  Eur J Endocrinol       Date:  2011-07-13       Impact factor: 6.664

2.  Connecting the Lines between Hypogonadism and Atherosclerosis.

Authors:  Akl C Fahed; Joanna M Gholmieh; Sami T Azar
Journal:  Int J Endocrinol       Date:  2012-02-16       Impact factor: 3.257

3.  12-months metabolic changes among gender dysphoric individuals under cross-sex hormone treatment: a targeted metabolomics study.

Authors:  Matthias K Auer; Alexander Cecil; Yasmin Roepke; Charlotte Bultynck; Charlotte Pas; Johannes Fuss; Cornelia Prehn; Rui Wang-Sattler; Jerzy Adamski; Günter K Stalla; Guy T'Sjoen
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.